Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Pridopidine 100 mg BID	7
Overall Study	STARTED	Pridopidine 150 mg BID	8
Overall Study	STARTED	Placebo	8
Overall Study	Treatment Group Based on Maximal Possible Highest Dose Received (Used for Analysis)	Pridopidine 100 mg BID	12
Overall Study	Treatment Group Based on Maximal Possible Highest Dose Received (Used for Analysis)	Pridopidine 150 mg BID	3
Overall Study	Treatment Group Based on Maximal Possible Highest Dose Received (Used for Analysis)	Placebo	8
Overall Study	COMPLETED	Pridopidine 100 mg BID	3
Overall Study	COMPLETED	Pridopidine 150 mg BID	3
Overall Study	COMPLETED	Placebo	4
Overall Study	NOT COMPLETED	Pridopidine 100 mg BID	4
Overall Study	NOT COMPLETED	Pridopidine 150 mg BID	5
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03922711/flow